5 completed, 1 not yet recruiting. 5 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Neurelis, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration NRL-1049, Placebo - Cerebral Cavernous Malformation | Phase 1 | Not yet recruiting | Neurelis, Inc. | 40 | 2026-11-11 | 2026-10-30 |
| A Study of Olanzapine After Intranasal and Intramuscular Administration olanzapine - Healthy | Phase 1 | Completed | Neurelis, Inc. | 24 | 2023-10-16 | 2024-09-19 |
| Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy Diazepam Nasal Spray [Valtoco] - Epilepsy | Phase 1 / Phase 2 | Completed | Neurelis, Inc. | 36 | 2021-11-08 | 2026-10-20 |
| Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects NRL-1 - Acute Repetitive Seizures | Phase 1 | Completed | Neurelis, Inc. | 57 | 2016-06-30 | 2021-10-05 |
| Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects NRL-1 - Acute Repetitive Seizures, Breakthrough Seizures | Phase 3 | Completed | Neurelis, Inc. | 175 | 2016-04-11 | 2022-01-31 |
| A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers Diazepam - Epilepsy | Phase 1 | Completed | University of Minnesota | 24 | 2011-02-01 | 2019-11-01 |
Epilepsy (4) · Seizures (2) · Hemangioma, Cavernous, Central Nervous System (1)
Diazepam (2) · Olanzapine (1)
United States (4) · Jordan (1)
PMID 34022621, PMID 34033266, PMID 34418086, PMID 35816831, PMID 37455404, PMID 38175488, PMID 40117564, PMID 40650667, PMID 41809194, PMID 42647177